9/102 sources · 2 publishersUpdated Oct 8, 14:30 UTC
Epkinly shows 51% risk reduction in Phase 3 frontline lymphoma trial
Genmab and AbbVie reported that their bispecific antibody Epkinly, combined with R‑CHOP chemotherapy, cut the risk of disease progression or death by 51% in a Phase 3 study of newly diagnosed diffuse large B‑cell lymphoma patients. The trial enrolled 900 participants at intermediate or high risk. The results position Epkinly for first‑line approval and could lift its sales.
Why it matters
Analysts note the data could significantly boost Epkinly’s sales, as the drug may become the first bispecific approved for first‑line DLBCL. Genmab’s shares jumped 14% on the news, reflecting investor optimism.
Key facts
- 1The Phase 3 trial enrolled 900 patients at intermediate or high risk of death. finance.yahoo.com
- 2Epkinly combined with R‑CHOP reduced the risk of disease progression or death by 51% relative to chemotherapy alone. finance.yahoo.com
- 3Genmab reported $312 million in global net sales of Epkinly in the first half of 2024. finance.yahoo.com
- 4Genmab’s shares rose as much as 14% following the announcement. finance.yahoo.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.